The Effect of Hemodialysis on Cardiac Biomarker Levels

Zaed Mohamed  Jaber; Naser Mohammed Irqayah

doi:10.54361/ljmr.2022

Authors

Zaed Mohamed Jaber Medical laboratory department, Higher Institute of Sciences and Medical Technology, Emsallata Author
Naser Mohammed Irqayah Medical laboratory department, Higher Institute of Sciences and Medical Technology, Emsallata Author

DOI:

https://doi.org/10.54361/ljmr.2022

Keywords:

Hemodialysis, serum total of troponin I (cTn-I), creatin phosphokinase (CPK), creatine kinase-MB (CK-MB) iso-enzyme

Abstract

Background: According to the United States Renal Data System (USRD), the 2013 Annual Data Report indicates that patients with chronic kidney disease (CKD) have higher rates of congestive heart failure, acute myocardial infraction (MI), and cerebral vascular accidents compared to non-CKD patients. Aim of the Study: This study aimed to investigate the effects of the hemodialysis process on cardiac biomarker levels in hemodialysis patients. Method: A prospective study was carried conducted at Emssalata central hospital's hemodialysis department. The study involved a total of 25 individuals, 15 males and 10 females who were undergoing dialysis. A chemistry analyzer was used to measure the serum troponin I (cTn-I), creatin phosphokinase (CPK), and creatine kinase-MB (CK-MB) iso-enzyme in hemodialysis (HD) patients before and after the dialysis process. Results: The results showed that total CPK, CK-MB, and cTn-I levels had no significant differences in CKD patients' pre and post-dialysis, with (p = 0.989, 0.586, and 0.284) respectively. Hemodialysis patients have none significantly higher CPK, CK-MB and cTn-I ratios after hemodialysis process when compared to the values determined to each marker before hemodialysis process. Conclusion: The dialysis process had no effect on the levels of cardiac biomarkers (CPK, CK-MB, and cTn-I) in hemodialysis patients. The cardiac biomarker in hemodialysis patients appears to be unaffected by age, gender, or dialysis duration

Downloads

Download data is not yet available.

References

Eknoyan, G., Lameire, N., Barsoum, R., Eckardt, K. U., Levin, A., Levin, N., Locatelli, F., MacLeod, A., Vanholder, R., Walker, R., & Wang, H. (2004). The burden of kidney disease: improving global outcomes. Kidney international, 66(4), 1310–1314.

Barreto, F. C., Stinghen, A. E., de Oliveira, R. B., Franco, A. T., Moreno, A. N., Barreto, D. V., Pecoits-Filho, R., Drüeke, T. B., & Massy, Z. A. (2014). The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 36(2), 221–235.

Vassalotti, J. A., Centor, R., Turner, B. J., Greer, R. C., Choi, M., Sequist, T. D., & National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2016). Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. The American journal of medicine, 129(2), 153–162.e7.

Kalantar-Zadeh K & Amin AN (2012). Toward more Accurate Detection and Risk Stratification of Chronic Kidney Disease. JAMA. 307(18):1976-7.

Mallett, A., Patel, C., Salisbury, A., Wang, Z., Healy, H., & Hoy, W. (2014). The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet journal of rare diseases, 9, 98.

Levey A.S.; Eckardt K.U.; Tsukamoto Y. et al. (2005). Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International. 67(6):2089-2100

National Kidney Foundation (2002). K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Am J Kidney Dis, Vol. 39, No. 2Suppl 1, pp. S1-266.

Shastri, S. & Sarnak, M.J (2010).Cardiovascular Disease and CKD: Core Curriculum. Am J Kidney Dis, 56, (2): p 399-417.

Ouyang, L., Bolen, J., Valdez, R., Joseph, D., Baum, M. A., & Thibadeau, J. (2015). Characteristics and survival of patients with end stage renal disease and spina bifida in the United States renal data system. The Journal of urology, 193(2), 558– 564.

Quiroga, B., Vega, A., Abad, S., Villaverde, M., Reque, J., & López-Gómez, J. M. (2016). Creatine-kinase and dialysis patients, a helpful tool for stratifying cardiovascular risk?. Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia, 36(1), 51–56.

Muharrem I1, Ebru G.O2, Tolga Y2.et.al (2014).The Effect of Hemodialysis on Cardiac Enzyme Levels. Department of Internal medicine. Int J Artif Organs. Sanliurfa, Turkey, 37(7): p513-520.eISSN:2413-6096

D'Marco, L., Bellasi, A., & Raggi, P. (2015). Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability. Disease markers, 2015, 586569.

Ingec, M., Oguz, E. G., Yildirim, T., Ulas, T., & Horoz, M. (2014). The effect of hemodialysis on cardiac enzyme levels and echocardiographic parameters. The International journal of artificial organs, 37(7), 513–520.

Bozbas, H., Korkmaz, M. E., Atar, I., Eroglu, S., Ozin, B., Yildirir, A., Muderrisoglu, H., Colak, T., Karakayali, H., & Haberal, M. (2004). Serum levels of cardiac enzymes before and after renal transplantation. Clinical cardiology, 27(10), 559– 562.

Naka, T., Wan, L., Bellomo, R., Wang, B. Z., Jones, R., Berry, R., Angus, P., & Gow, P. (2004). Kidney failure associated with liver transplantation or liver failure: the impact of continuous veno-venous hemofiltration. The International journal of artificial organs, 27(11), 949–955

Quiroga, B., Vega, A., Abad, S., Villaverde, M., Reque, J., & López-Gómez, J. M. (2016). Creatine-kinase and dialysis patients, a helpful tool for stratifying cardiovascular risk?. Nefrologia : publica